atorvastatin has been researched along with Cancer of Head in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HK; Chu, YH; Liao, AH; Lin, WT; Shih, CP; Wang, CH | 1 |
| Allen, P; Brewer, C; Campbell, M; Cheng, H; Clements, A; Cunningham, LL; Dubno, JR; Fernandez, KA; Garrett, J; Li, CM; Mulford, D; Mulquin, M; Newlands, S; Ortiz, C; Page, B; Schmitt, NC; Townes, T | 1 |
| Islam, M; Kumar, B; Sharma, S; Teknos, TN | 1 |
1 trial(s) available for atorvastatin and Cancer of Head
| Article | Year |
|---|---|
Atorvastatin is associated with reduced cisplatin-induced hearing loss.
Topics: Aged; Atorvastatin; Cisplatin; Female; Head and Neck Neoplasms; Hearing Loss; Humans; Incidence; Male; Middle Aged; Ototoxicity; Prospective Studies; Retrospective Studies | 2021 |
2 other study(ies) available for atorvastatin and Cancer of Head
| Article | Year |
|---|---|
Synergistic effects of combined treatment with ultrasound-mediated cisplatin-loaded microbubbles and atorvastatin on head and neck cancer.
Topics: Atorvastatin; Cell Line, Tumor; Cisplatin; Head and Neck Neoplasms; Humans; Microbubbles; Ultrasonography | 2021 |
Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.
Topics: Animals; Atorvastatin; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Phosphorylation; Pyrroles; rho GTP-Binding Proteins; rhoC GTP-Binding Protein; STAT3 Transcription Factor | 2013 |